keyword
MENU ▼
Read by QxMD icon Read
search

radioactive iodine refractory

keyword
https://www.readbyqxmd.com/read/29317481/iaps-cause-resistance-to-trail-dependent-apoptosis-in-follicular-thyroid-cancer
#1
Thomas Artur Werner, Inga Nolten, Levent Dizdar, Jasmin Riemer, Sina Christin Schütte, Pablo Emilio Verde, Katharina Raba, Matthias Schott, Wolfram Trudo Knoefel, Andreas Krieg
Follicular thyroid cancer's (FTC) excellent long-term prognosis is mainly dependent on complete surgical removal and postoperative radioactive iodine (RAI) treatment. However, once the tumour becomes RAI refractory the 10-year disease specific survival rate drops below 10 %. The aim of our study was to evaluate the prognostic and biological role of the TRAIL system in FTC and to elucidate the influence of small molecule mediated antagonization of inhibitor of apoptosis proteins (IAPs) on TRAIL-sensitivity in vitro...
January 9, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29302491/an-ectopic-intrathyroidal-thymic-tissue-and-intrathymic-parathyroid-tissue-in-a-patient-with-graves-disease
#2
Kelly O'Connor, Hassan Alzahrani, Fadi Murad, Philip Daroca, Emad Kandil
Ectopic intrathyroidal thymic tissue, with coinciding intrathymic parathyroid tissue, is a very rare occurrence that is most often found incidentally in adults during surgery. We report a 23-year-old female who presented with Graves disease refractory to medical treatment. Radioactive iodine uptake demonstrated increased, diffuse uptake in the region of the thyroid. The patient underwent a total thyroidectomy and right inferior parathyroidectomy which was found enlarged intraoperatively. Histopathologically, surgical specimen demonstrated characteristics of intrathyroidal thymic tissue and intrathymic parathyroid tissue...
December 2017: Gland Surgery
https://www.readbyqxmd.com/read/29301825/genomic-correlates-of-response-to-everolimus-in-aggressive-radioiodine-refractory-thyroid-cancer-a-phase-ii-study
#3
Glenn J Hanna, Naifa L Busaidy, Nicole G Chau, Lori J Wirth, Justine A Barletta, Antonio Calles, Robert I Haddad, Stefan Kraft, Maria E Cabanillas, Guilherme Rabinowits, Anne O'Neill, Sewanti A Limaye, Erik K Alexander, Francis D Moore, Krzysztof Misiukiewicz, Tom Thomas, Matthew A Nehs, Ellen Marqusee, Stephanie L Lee, Pasi A Janne, Jochen H Lorch
PURPOSE: Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer (TC). We evaluated the efficacy of everolimus in aggressive, radioactive iodine refractory (RAIR) TC and correlated tumor mutational profiling with response. Exploratory medullary and anaplastic TC cohorts were included. EXPERIMENTAL DESIGN: This single-arm, multi-institutional phase II study was conducted from 2009-2013 in patients with incurable RAIR TC who had radiographic progression six months prior to enrollment...
January 4, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29262462/-progress-in-diagnosis-and-treatment-of-radioactive-iodine-refractory-differentiated-thyroid-carcinoma
#4
Z Zhao, G H Shen, Y H Li, K Zhou, H W Cai
The radioactive iodine-refractory differentiated thyroid carcinoma (RIR-DTC) is a complex process that involves multiple genetic changes and multiple signaling pathways.Radionuclide imaging, genomics and proteomics are effective to clarify the mechanism and helpful in clinical diagnosis and therapy.The treatment of RIR-DTC includes the removal of distant metastases, drug therapy, external radiotherapy and radiofrequency ablation.This review mainly focuses on the pathogenesis, diagnosis and treatment of RIR-DTC...
December 7, 2017: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/29243843/signaling-cascades-in-thyroid-cancer-increasing-the-armory-of-archers-to-hit-bullseye
#5
Faiza Abdul Rashid, Qaisar Mansoor, Hafsa Aziz, Sobia Tabassum, Waleed O Arfat, George E Naoum, Muhammad Ismail, Ammad Ahmad Farooqi
Thyroid cancer is a multifaceted and therapeutically challenging disease and rapidly accumulating experimentally verified findings have considerably improve our understanding of the molecular mechanisms which underlie its development. Substantial fraction of information has been added into existing landscape of molecular oncology and we have started to develop a sharper understanding of the underlying mechanisms of thyroid cancer. Wealth of information demystified different intracellular signaling cascades which are frequently deregulated in thyroid cancer...
December 15, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29209273/updates-on-the-management-of-advanced-metastatic-and-radioiodine-refractory-differentiated-thyroid-cancer
#6
REVIEW
Dario Tumino, Francesco Frasca, Kate Newbold
Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating hormone suppressive therapy. However, 5-10% of patients have advanced disease, with aerodigestive tract invasion, distant metastases, or radioiodine refractory disease, with poor prognosis. This review focuses on the approaches for treating advanced DTC, including management of gross extra-thyroidal extension, recurrent loco-regional or distant metastatic disease, the role of external beam radiation therapy and systemic treatment...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29162036/sorafenib-treatment-for-papillary-thyroid-carcinoma-with-diffuse-lung-metastases-in-a-child-with-autism-spectrum-disorder-a-case-report
#7
Yousuke Higuchi, Takayuki Motoki, Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Takanori Oyama, Takuo Noda, Yasuko Tsurumaru, Ayumi Okada, Hirokazu Tsukahara, Akira Shimada
BACKGROUND: Pediatric papillary thyroid carcinoma frequently presents with lymph node involvement and distant metastases. Sorafenib, an oral multikinase inhibitor, has been used to treat radioactive iodine (RAI) therapy-refractory thyroid carcinoma in adults; however, pediatric experience is limited. Medical procedures and hospitalization for children with autism spectrum disorder may be challenging. CASE PRESENTATION: An 11-year-old boy with autism spectrum disorder and moderate intellectual impairment presented with dyspnea on exertion with thyroid carcinoma and diffuses lung metastases...
November 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29092022/pulmonary-metastasectomy-for-thyroid-cancer-as-salvage-therapy-for-radioactive-iodine-refractory-metastases
#8
Isabelle Moneke, Jussuf T Kaifi, Raphael Kloeser, Patrick Samson, Benedikt Haager, Sebastian Wiesemann, Sven Diederichs, Bernward Passlick
OBJECTIVES: Distant metastasis arising from thyroid cancer is rare but has been associated with significantly reduced long-term survival, especially when refractory to radioactive iodine ablation. We provide one of the largest studies worldwide reporting the outcome after salvage pulmonary metastasectomy for this entity, aiming to identify prognostic factors and to analyse surgical indication. METHODS: We retrospectively analysed the medical records of 43 patients who had undergone pulmonary metastasectomy for radioactive iodine-refractory thyroid cancer from 1985 to 2016...
October 30, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28988510/tyrosine-kinase-inhibitors-rechallenge-in-solid-tumors-a-review-of-literature-and-a-case-description-with-lenvatinib-in-thyroid-cancer
#9
REVIEW
Francesco Felicetti, Alice Nervo, Alessandro Piovesan, Rita Berardelli, Filippo Marchisio, Marco Gallo, Emanuela Arvat
In the last decade tyrosine kinase inhibitors (TKIs) have been employed for a wide range of hematological and solid tumors and today they represent a valid therapeutic option for different neoplasms. Among them, both sorafenib and lenvatinib were approved for the treatment of radioactive iodine (RAI) refractory differentiated thyroid carcinoma (DTC). Unfortunately, in some cases the efficacy of TKIs is limited by the onset of drug resistance after the initial response. Areas covered: We report the case of a patient with a RAI refractory advanced DTC, treated with lenvatinib after surgery, multiple RAI administrations, traditional chemotherapy, and sorafenib...
December 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28920557/automated-microspect-microct-image-analysis-of-the-mouse-thyroid-gland
#10
Peng Cheng, Brynn Hollingsworth, Daniel Scarberry, Daniel H Shen, Kimerly Powell, Sean C Smart, John Beech, Xiaochao Sheng, Lawrence S Kirschner, Chia-Hsiang Menq, Sissy M Jhiang
BACKGROUND: The ability of thyroid follicular cells to take up iodine enables the use of radioactive iodine (RAI) for imaging and targeted killing of RAI-avid thyroid cancer following thyroidectomy. To facilitate identifying novel strategies to improve (131)I therapeutic efficacy for patients with RAI refractory disease, it is desired to optimize image acquisition and analysis for preclinical mouse models of thyroid cancer. METHODS: A customized mouse cradle was designed and used for microSPECT/CT image acquisition at 1 hour (t1) and 24 hours (t24) post injection of (123)I, which mainly reflect RAI influx/efflux equilibrium and RAI retention in the thyroid, respectively...
November 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28911726/novel-concepts-for-initiating-multitargeted-kinase-inhibitors-in-radioactive-iodine-refractory-differentiated-thyroid-cancer
#11
REVIEW
R Michael Tuttle, Marcia S Brose, Enrique Grande, Sun Wook Kim, Makoto Tahara, Mona M Sabra
Multitargeted kinase inhibitors have been shown to improve progression-free survival in patients with structurally progressive, radioactive iodine refractory differentiated thyroid cancer. While the inclusion criteria for phase 3 clinical trials and clinical practice guidelines provide guidance with regard to the minimal requirements that need to be met prior to initiation of a multitargeted kinase inhibitor, a better way to integrate the rate of structural disease progression with the size of the metastatic foci to more precisely define the optimal time to recommend initiation of therapy for individual patients is needed...
June 2017: Best Practice & Research. Clinical Endocrinology & Metabolism
https://www.readbyqxmd.com/read/28881369/-molecular-pathogenesis-of-thyroid-nodules-relevance-for-clinical-care
#12
D Führer, T Musholt, K W Schmid
Thyroid nodules represent heterogeneous tumors with distinct molecular signatures. While benign thyroid nodules correspond to poly- or monoclonal tumors, thyroid carcinomas are monoclonal and thus "real" neoplasms. These are caused by somatic mutations that lead to the constitutive activation of specific signaling cascades and determine the corresponding histology and also partly the functional phenotype of the thyroid tumor. Dedifferentiation of thyroid carcinomas is accompanied by the occurrence of additional mutations in the tumors...
September 2017: Laryngo- Rhino- Otologie
https://www.readbyqxmd.com/read/28844117/well-differentiated-thyroid-cancer-neovasculature-expresses-prostate-specific-membrane-antigen-a-possible-novel-therapeutic-target
#13
Maureen Moore, Suraj Panjwani, Rashmi Mathew, Michael Crowley, Yi-Fang Liu, Anna Aronova, Brendan Finnerty, Rasa Zarnegar, Thomas J Fahey, Theresa Scognamiglio
Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein receptor, is highly expressed in prostate cancer and in the tumor neovasculature of colon, breast, and adrenocortical tumors. Here, we analyzed PSMA expression in the neovasculature of various thyroid cancer subtypes and assessed whether PSMA expression is correlated with aggressive behavior. From a prospectively maintained database, we evaluated 91 samples from 68 patients, including 37 primary differentiated thyroid cancers (DTCs) [11 classic papillary (cPTC), 9 follicular-variant (FvPTC), 11 follicular (FTC), 6 radioactive iodine-refractory (RAIR)], 5 anaplastic (ATC) carcinomas, 9 distant and 12 lymph node metastases, 21 benign thyroid nodules, and 7 normal thyroid specimens...
December 2017: Endocrine Pathology
https://www.readbyqxmd.com/read/28741453/no-effect-of-levothyroxine-and-levothyroxine-induced-subclinical-thyrotoxicosis-on-the-pharmacokinetics-of-sorafenib-in-healthy-male-subjects
#14
Funan Huang, Antoinette Ajavon, Erya Huang, John Lettieri, Rong Liu, Carol Peña, Matthias Berse
BACKGROUND: Patients receiving the multikinase inhibitor sorafenib for locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine often receive concomitant levothyroxine for thyrotropin (TSH) suppression. In the Phase 3 DTC trial (DECISION), sorafenib exposure was approximately twofold higher than that observed in other cancers. This study assessed sorafenib pharmacokinetics without and with concomitant levothyroxine to examine whether a levothyroxine interaction or levothyroxine-induced subclinical thyrotoxicosis results in increased sorafenib exposure in patients with DTC...
September 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28704384/quantitative-thyroglobulin-response-to-radioactive-iodine-treatment-in-predicting-radioactive-iodine-refractory-thyroid-cancer-with-pulmonary-metastasis
#15
Chen Wang, Xin Zhang, Hui Li, Xin Li, Yansong Lin
OBJECTIVE: Current diagnosis of radioactive iodine (RAI)-refractory (RAIR) differentiated thyroid cancer (DTC) is based on the imaging technique, which is of a high cost. Serum thyroglobulin (Tg) is a sensitive and easily obtained biomarker. Hence, we aimed to assess the predicting value of quantitative response of Tg in earlier identifying the RAIR-DTC with pulmonary metastasis. PATIENTS AND METHODS: Pulmonary metastatic DTC patients who underwent total or near-total thyroidectomy and at least two times of RAI therapy were included in this study...
2017: PloS One
https://www.readbyqxmd.com/read/28687563/axitinib-treatment-in-advanced-rai-resistant-differentiated-thyroid-cancer-dtc-and-refractory-medullary-thyroid-cancer-mtc
#16
Jaume Capdevila, José Manuel Trigo, Javier Aller, José Luís Manzano, Silvia García Adrián, Carles Zafón Llopis, Òscar Reig, Uriel Bohn, Teresa Ramón Y Cajal, Manuel Duran-Poveda, Beatriz González Astorga, Ana López-Alfonso, Javier Medina Martínez, Ignacio Porras, Juan Jose Reina, Nuria Palacios, Enrique Grande, Elena Cillán, Ignacio Matos, Juan Jose Grau
BACKGROUND: Axitinib, an antiangiogenic multikinase inhibitor (MKI), was evaluated in the compassionate use programme (CUP) in Spain (October 2012-November 2014). SUBJECTS AND METHODS: 47 patients with advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC, n = 34) or medullary thyroid cancer (MTC, n = 13) with documented disease progression were treated with axitinib 5 mg b.i.d. The primary efficacy endpoint was objective response rate (ORR) by Response Evaluation Criteria In Solid Tumors (RECIST) v1...
October 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28687430/management-of-the-lateral-neck-in-well-differentiated-thyroid-cancer
#17
REVIEW
J R Cracchiolo, R J Wong
Lateral neck lymph node metastases in well differentiated thyroid cancer are common, ranging from 30% to 60%, with the majority of these foci identifiable only as microscopic deposits. A skilled ultrasound evaluation of the lymph nodes in the lateral neck is recommended for all patients presenting with newly diagnosed thyroid cancer undergoing surgical management. Ultrasound guided fine needle aspiration biopsy may be used to cytologically confirm suspected lateral neck nodal metastases prior to surgery. For patients with large volume nodal disease, extranodal extension, or multiple nodal metastases, computed tomography (CT) scan of the neck with contrast is an important additional imaging modality to accurately localize disease prior to surgery...
June 22, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28662274/phase-2-study-evaluating-the-combination-of-sorafenib-and-temsirolimus-in-the-treatment-of-radioactive-iodine-refractory-thyroid-cancer
#18
Eric J Sherman, Lara A Dunn, Alan L Ho, Shrujal S Baxi, Ronald A Ghossein, Matthew G Fury, Sofia Haque, Cami S Sima, Grace Cullen, James A Fagin, David G Pfister
BACKGROUND: Patients with recurrent and/or metastatic, radioactive iodine-refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase inhibitor, is approved by the US Food and Drug Administration for the treatment of radioactive iodine-refractory thyroid carcinoma, although it demonstrated low response rates (12.2%) as a single agent in the first-line setting. The objective of the current study was to determine whether adding the mammalian target of rapamycin inhibitor temsirolimus to sorafenib could improve on these results...
November 1, 2017: Cancer
https://www.readbyqxmd.com/read/28635560/sorafenib-in-japanese-patients-with-locally-advanced-or-metastatic-medullary-thyroid-carcinoma-and-anaplastic-thyroid-carcinoma
#19
Yasuhiro Ito, Naoyoshi Onoda, Ken-Ichi Ito, Iwao Sugitani, Shunji Takahashi, Iku Yamaguchi, Koki Kabu, Katsuya Tsukada
BACKGROUND: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (DTC). An uncontrolled, open-label, multicenter, single-arm, Phase 2 clinical study was conducted to evaluate the safety and efficacy of sorafenib in Japanese patients with MTC and ATC...
September 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28635520/information-for-clinicians-approach-to-the-patient-with-progressive-radioactive-iodine-refractory-thyroid-cancer-when-to-use-systemic-therapy
#20
Maria Cabanillas, David James Terris, Mona Sabra
N/A.
June 21, 2017: Thyroid: Official Journal of the American Thyroid Association
keyword
keyword
117482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"